Mirogabalin

Phase 3Small molecule

Daiichi Sankyo

Mirogabalin is one of 96 small molecule programs targeting Peripheral Neuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral NeuropathyActive, not recruiting

Neuropathic PainRecruiting

FibromyalgiaRecruiting

Peripheral NeuropathyPreclinical

Active, not recruiting

Neuropathic PainPhase 3

Recruiting

FibromyalgiaPreclinical

Recruiting

Competition

Competitive Landscape

52 competitors in Neuropathic Pain

#DrugCompanyPhaseTrials

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

44 2

Cymbalta

Jazz Pharmaceuticals

Approved

10 3

Trileptal

Novartis

Approved

2 4

Neurontin

VViatris Specialty LLC

Approved

10 5

Ketalar

AAultman Health Foundation

Approved

9 6

Aricept

Eisai

Approved

1 7

Lioresal

Savella

Epidiolex

Depakote

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalRecruiting

Neuropathic Pain

NCT07451431

Q3 2027

PreclinicalRecruiting

Fibromyalgia

NCT07157852

Clinical

Trials by Indication[1]

Neuropathic Pain3 trials

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT04094662·393 enrolled

Study of Mirogabalin for Central Neuropathic Pain

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT03901352·300 enrolled

Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain

Recruiting·—·Phase 4·NCT07451431·78 enrolled

Peripheral Neuropathy1 trial

Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer Survivors

Not yet recruiting·PPusan National University Yangsan Hospital·N/A·NCT06711978·66 enrolled

Pain1 trial

Comparison Efficacy of Mirogabalin and Pregabalin in Total Knee Arthroplasty. a Randomized Controlled Trial

Recruiting·TThammasat University Hospital·Preclinical·NCT06328062·80 enrolled

Fibromyalgia1 trial

Comparing the Efficacy and Safety of Pregabalin Monotherapy Versus Other Neuromodulatory Drugs (Mirogabalin) in the Treatment of Fibromyalgia: A Multicenter Clinical Study

Recruiting·BBeijing Tiantan Hospital·Preclinical·NCT07157852·674 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Mirogabalin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mirogabalin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mirogabalin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Daiichi Sankyo

Mirogabalin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Neuropathic Pain3 trials

Peripheral Neuropathy1 trial

Pain1 trial

Fibromyalgia1 trial

References

Drug Info

Quick Facts

Related News